Braverman L E, Ingbar S H, Sterling K
J Clin Invest. 1970 May;49(5):855-64. doi: 10.1172/JCI106304.
Studies of the possibility that thyroxine (T4) is converted to 3.5,3'-triiodo-L-thyronine (T3) in the extrathyroidal tissues in man have been conducted in 13 patients, all but two of whom were athyreotic or hypothyroid, and all of whom were receiving at least physiological replacement doses of synthetic sodium-L-thyroxine.T3 was found in the sera of all patients, in concentrations ranging between 243 and 680 ng/100 ml (normal range 170-270 ng/100 ml). These concentrations were far in excess of those which would have been expected on the basis of the T3 contamination of the administered T4, as measured by the same technique employed in the analysis of serum. When oral medication was enriched with (125)I-labeled T4 for 8 or more days, labeled T3 and tetraiodothyroacetic acid (Tetrac or TA(4)) were found in the serum to the extent of approximately 2-5% of total radioactivity, as assessed by unidimensional paper chromatography. The same results were obtained with a specially purified lot of radioactive T4 containing less than 0.1% T3 as a contaminant. The identities of the (125)I-labeled T3 and TA(4) were verified by two-dimensional chromatography as well as by specific patterns of binding in serum. The labeled T3 isolated was bound by albumin and by T4-binding globulin (TBG), but not by T4-binding prealbumin (TBPA): in contrast the labeled TA(4) was bound by albumin and TBPA, but not by TBG. To exclude the possibility that the conversion of T4 to T3 was a peculiarity of the oral route of administration, the sera of two additional patients were obtained 48 hr after 7-day courses of daily intravenous injections of a mixture of stable and (125)I-labeled T4. Both stable and labeled T3 were likewise found in these sera. In contrast to earlier experiments in humans in which (131)I-labeled T3 was not definitively demonstrated in serum after a single intravenous injection of (131)I-labeled T4, the present findings are taken to provide conclusive evidence of the extrathyroidal conversion of T4 to T3 in man. These results raise once again the question of the extent to which the metabolic effect of T4 is mediated through the peripheral generation of T3.
对13名患者进行了研究,以探讨甲状腺素(T4)在人体甲状腺外组织中是否会转化为3,5,3'-三碘-L-甲状腺原氨酸(T3)。除两名患者外,其余患者均为无甲状腺或甲状腺功能减退患者,且所有患者均接受至少生理替代剂量的合成L-甲状腺素钠。所有患者血清中均检测到T3,浓度范围为243至680 ng/100 ml(正常范围为170 - 270 ng/100 ml)。这些浓度远远超过根据血清分析中使用的相同技术测量的所给予T4中的T3污染量所预期的浓度。当口服药物用(125)I标记的T4富集8天或更长时间时,通过单向纸色谱法评估,血清中发现标记的T3和四碘甲状腺乙酸(Tetrac或TA(4))的量约占总放射性的2 - 5%。使用一批特别纯化的放射性T4(污染物T3含量低于0.1%)也得到了相同的结果。(125)I标记的T3和TA(4)的身份通过二维色谱法以及血清中的特异性结合模式得到了验证。分离出的标记T3与白蛋白和甲状腺素结合球蛋白(TBG)结合,但不与甲状腺素结合前白蛋白(TBPA)结合:相比之下,标记的TA(4)与白蛋白和TBPA结合,但不与TBG结合。为排除T4转化为T3是口服给药途径所特有的可能性,在另外两名患者每日静脉注射稳定的和(125)I标记的T4混合物7天疗程后的48小时采集血清。这些血清中同样发现了稳定的和标记的T3。与早期在人体中进行的实验不同,早期实验中单次静脉注射(131)I标记的T4后血清中未明确检测到(131)I标记的T3,目前的研究结果被视为提供了人体甲状腺外T4转化为T3的确凿证据。这些结果再次引发了T4的代谢作用在多大程度上是通过外周生成T3介导的问题。